Management of primary sclerosing cholangitis

Area of Science:

• Hepatology
• Gastroenterology
• Autoimmune Liver Diseases

Background:

• Primary sclerosing cholangitis (PSC) is a rare, progressive cholestatic liver disease associated with significant morbidity and mortality.
• Current therapeutic strategies for PSC lack conclusive evidence, complicating patient management.
• High-dose ursodeoxycholic acid (UDCA), previously considered beneficial, has shown adverse effects in advanced PSC stages.

Purpose of the Study:

• To review current therapeutic options for primary sclerosing cholangitis (PSC).
• To evaluate the efficacy and limitations of existing and emerging treatments for PSC.
• To highlight challenges in managing PSC, including dominant bile duct stenoses and cholangiocarcinoma (CCC).

Main Methods:

• Review of existing literature on PSC pharmacotherapy and interventions.
• Analysis of the role of UDCA, immunosuppressants, and endoscopic treatments.
• Discussion of diagnostic and therapeutic challenges posed by cholangiocarcinoma (CCC) in PSC patients.

Main Results:

• High-dose UDCA is not recommended for advanced PSC due to negative effects.
• Immunosuppressants may benefit PSC patients with overlap syndromes.
• Endoscopic treatment is indicated for dominant bile duct stenoses.

Conclusions:

• PSC management requires individualized approaches due to heterogeneous disease progression.
• Cholangiocarcinoma (CCC) in PSC remains a therapeutic challenge, necessitating improved early diagnosis.
• Novel strategies like neoadjuvant radiochemotherapy and liver transplantation are potential options for selected CCC patients.